Provided by Tiger Fintech (Singapore) Pte. Ltd.

Indaptus Therapeutics, Inc.

0.8051
-0.0017-0.21%
Post-market: 0.81990.0148+1.84%18:18 EDT
Volume:6.60K
Turnover:5.33K
Market Cap:11.37M
PE:-0.47
High:0.8180
Open:0.8176
Low:0.7800
Close:0.8068
Loading ...

Indaptus Therapeutics FY24 EPS $(1.61) Up From $($1.83) YoY

Benzinga
·
13 Mar

BRIEF-Indaptus Therapeutics reports full-year loss of $1.61 per share

Reuters
·
13 Mar

Indaptus Therapeutics FY EPS USD -1.61

THOMSON REUTERS
·
13 Mar

Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Dow Jones
·
13 Mar

BRIEF-Indaptus Therapeutics Expands Patent Portfolio In China, Japan, And Israel, Strengthening Its Intellectual Property For Infectious Disease And Cancer Treatments

Reuters
·
04 Mar

Indaptus Therapeutics expands patent portfolio in China, Japan, Israel

TIPRANKS
·
04 Mar

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening Its Intellectual Property for Infectious Disease and Cancer Treatments

THOMSON REUTERS
·
04 Mar

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

GlobeNewswire
·
04 Mar

Indaptus Therapeutics Enters Standby Equity Purchase Deal With YA II PN

MT Newswires Live
·
13 Feb

BRIEF-Indaptus Therapeutics Enters Equity Purchase Agreement With Ya II Pn

Reuters
·
12 Feb

Indaptus Therapeutics Inc - Can Sell up to $20 Million of Stock to Yorkville

THOMSON REUTERS
·
12 Feb

Indaptus Therapeutics Inc - Enters Equity Purchase Agreement With Ya Ii Pn

THOMSON REUTERS
·
12 Feb

BRIEF-Indaptus Therapeutics Files Prospectus Relating To Proposed Resale By Selling Stockholders Of Up To 4.4 Million Shares

Reuters
·
06 Feb

Indaptus Therapeutics Inc: Files Prospectus Relating to Proposed Resale by Selling Stockholders of up to 4.4 Mln Shares

THOMSON REUTERS
·
06 Feb

Indaptus Therapeutics Says Health Canada Approves Start of Lead Asset Decoy20 Trial

MT Newswires Live
·
05 Feb

Indaptus Therapeutics Receives Approval From Health Canada to Expand Clinical Trial of Decoy20

THOMSON REUTERS
·
05 Feb